tradingkey.logo

Medicus Pharma Ltd

MDCX
View Detailed Chart
2.300USD
+0.100+4.55%
Close 11/05, 16:00ETQuotes delayed by 15 min
36.65MMarket Cap
LossP/E TTM

Medicus Pharma Ltd

2.300
+0.100+4.55%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.55%

5 Days

0.00%

1 Month

-9.45%

6 Months

-46.14%

Year to Date

-5.35%

1 Year

0.00%

View Detailed Chart

TradingKey Stock Score of Medicus Pharma Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Medicus Pharma Ltd's Score

Industry at a Glance

Industry Ranking
127 / 173
Overall Ranking
478 / 4682
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
22.333
Target Price
+915.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Medicus Pharma Ltd Highlights

StrengthsRisks
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -1.82, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.10M shares, decreasing 31.52% quarter-over-quarter.

Medicus Pharma Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Medicus Pharma Ltd Info

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
Ticker SymbolMDCX
CompanyMedicus Pharma Ltd
CEODr. Raza Bokhari, M.D.
Websitehttps://medicuspharma.com/
KeyAI